

Date and time: Tuesday 22 July 2014, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting **Diagnosis and monitoring of asthma**
11

Place: **Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ**

Present: John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
Tara Burn, Patient member
Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric
Respiratory Medicine
Ren Gilmartin, Respiratory Nurse Specialist
Val Hudson, Patient member
Matthew Masoli, Consultant Respiratory Physician
Melanie McFeeters, Consultant Nurse in Children’s Respiratory
Diseases
Andrew Menzies-Gow (Chair), Consultant in Respiratory Medicine
Tahmina Siddiqui, General Practitioner partner
Michael Thomas, Professor of Primary Care Research & Principal in
General Practice (present for item 3 onwards)
Emily Davies, Senior Research Fellow, NCGC
Alex Haines, Health Economist, NCGC
Martin Harker, Senior Health Economist, NCGC
Emma Madden, Research Fellow, NCGC
Jill Parnham, Operations Director, NCGC
Amelia Unsworth, Project Manager, NCGC (notes)
Giulia Zuodar, Document Editor/Process Assistant, NCGC (present
for item 6 onwards)

Apologies: Bernard Higgins, Clinical Director, NCGC
Angela Key, Chief Respiratory Physiologist
Paul Miller, Senior Information Scientist, NCGC
Georgina Russell, RCP Clinical Fellow (Specialist Trainee Adviser)

In attendance:

NICE Staff: NICE attendee 1	Caroline Keir, Guidelines Commissioning Manager	
NICE attendee 2	Gareth Haman, Senior Medical Editor (present for item 6 onwards)	

Observers:

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the eleventh meeting of this GDG. Apologies were received from AK, BH, PM and GR.

The Chair reviewed and requested updates to the declarations of interest register. AMG declared his attendance at one advisory board for Boehringer Ingelheim to discuss the use of Tiotropium in severe asthma. AMG also received lecture fees from NAPP for a talk on the use of Flutiform in asthma, from GlaxoSmithKline for a talk about Real Life clinical trials and the Salford Lung Study, and from Chiesi for a talk about the management of severe asthma. These declarations of interest were classified as non-specific personal pecuniary interests and the guideline lead agreed that no further action was required.

MT declared that his department has received an honorarium from Aerocrine for his attendance at an advisory meeting to discuss research needs in the FeNO evidence and a possible Horizon 2020 grant application for a multinational collaborative EU-Industry funded project. This declaration of interest was classified as a specific non-personal pecuniary interest and the Chair agreed that MT's withdrawal from all discussions on FeNO (and only respond to direct questions of fact on request by the Chair) should continue for the next 12 months in accordance with the NICE code of practice for declaring and dealing with conflicts of interest. In addition, MT's department has received funding from GSK as MT is the chief investigator and chair of the steering committee of an international study investigating inhaler device errors. This declaration of interest was classified as a non-specific non-personal pecuniary interest and the Chair agreed that no further action was required. MT has received an honorarium from Boehringer Ingelheim for attendance at a meeting organising a collaborative project with the University of Nottingham/PRIMIS to create an asthma electronic audit tool for use in general practice, and from Novartis for speaking at meeting on COPD. These declarations of interest were classified as non-specific personal pecuniary interests and the Chair agreed that no further action was required.

JA declared that he received payments from Abbvie for a lecture on RSV and for an advisory board on preventing RSV admissions. These declarations of interest were classified as non-specific personal pecuniary interests and the Chair agreed that no further action was required.

No other new declarations of interest were received and therefore no further action was required. No new declarations of interest were received and therefore no further action was required.

2. **GDG10 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Review linking evidence to recommendations**

The GDG reviewed the linking evidence to recommendations for telehealthcare, inhaler technique, blood eosinophils for monitoring and challenge tests for monitoring.

4. **Evidence review: lung function tests for monitoring**

Notes

The GDG reviewed the evidence on the clinical and cost effectiveness of lung function tests for monitoring.

5. **Evidence review: FeNO for monitoring**

The GDG reviewed the evidence on the clinical and cost effectiveness of FeNO for monitoring.

(Note: MT did not formally participate in this discussion except to answer direct questions of fact as requested by the Chair).

6. **HE model: results**

The GDG was given a presentation on the final results of the health economic model for asthma diagnosis.

7. **Writing NICE guideline recommendations**

The GDG was given a presentation on writing NICE guideline recommendations and on the different versions of the guideline (full guideline, NICE version, information for the public and the NICE pathway).

8. **Diagnostic pathway, draft recommendations & future research recommendations**

The GDG reviewed the diagnostic pathway, draft recommendations and the draft future research recommendations.

9. **Any other business**

None.

Date, time and venue of the next meeting

Tuesday 2 September 2014, 1000-1600 at NCGC, 180 Great Portland Street, London W1W 5QZ